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Abstract
Background: Secreted Protein Acidic and Rich in Cysteine (SPARC) is expressed during tissue repair and regulates cellular
proliferation, migration and cytokine expression. The aim was to determine if SPARC modifies intestinal inflammation.
Methods: Wild-type (WT) and SPARC-null (KO) mice received 3% dextran sodium sulphate (DSS) for 7 days. Inflammation
was assessed endoscopically, clinically and histologically. IL-1b, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-12/IL23p40, TNF-a, IFN-c,
RANTES, MCP-1, MIP-1a, MIP-1b, MIG and TGF-b1 levels were measured by ELISA and cytometric bead array. Inflammatory
cells were characterised by CD68, Ly6G, F4/80 and CD11b immunofluorescence staining and regulatory T cells from spleen
and mesenteric lymph nodes were assessed by flow cytometry.
Results: KO mice had less weight loss and diarrhoea with less endoscopic and histological inflammation than WT animals.
By day 35, all (n = 13) KO animals completely resolved the inflammation compared to 7 of 14 WT mice (p,0.01). Compared
to WTs, KO animals at day 7 had less IL1b (p = 0.025) and MIG (p = 0.031) with higher TGFb1 (p = 0.017) expression and a
greater percentage of FoxP3+ regulatory T cells in the spleen and draining lymph nodes of KO animals (p,0.01). KO mice
also had fewer CD68+ and F4/80+ macrophages, Ly6G+ neutrophils and CD11b+ cells infiltrating the inflamed colon.
Conclusions: Compared to WT, SPARC KO mice had less inflammation with fewer inflammatory cells and more regulatory T
cells. Together, with increased TGF-b1 levels, this could aid in the more rapid resolution of inflammation and restoration of
the intestinal mucosa suggesting that the presence of SPARC increases intestinal inflammation.
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Introduction
The Inflammatory Bowel diseases (IBDs), Crohn’s disease and
ulcerative colitis are chronic inflammatory disorders that affect the
human gastrointestinal tract. Numerous murine models have been
developed to investigate the pathology that underlies IBD
inflammation and the dextran sodium sulphate (DSS)-induced
model of colitis is one of the most widely used. DSS is directly toxic
to gut epithelial cells located within basal crypts, and reduces
mucosal barrier integrity allowing the translocation of antigens
from the intestinal lumen into the submucosa. The presence of
luminal antigens in the intestinal mucosa can then promote acute
inflammation with recruitment, and activation, of immune cells
[1,2]. While the destructive effects of DSS are generally reversible
upon DSS withdrawal [3], the administration of DSS to mice over
an extended period of time can induce chronic intestinal
inflammation with symptoms and histological features similar to
those observed in human IBD [1,4,5].
Secreted protein acidic and rich in cysteine (SPARC) is a
matricellular glycoprotein involved in diverse biological processes,
including tissue remodelling, wound repair, angiogenesis as well as
cellular differentiation, adhesion, proliferation and migration [6–
8]. A deficiency in SPARC has been associated with a reduction in
both renal inflammation and fibrosis [9], but these effects may not
be universal across different tissues as demonstrated by the
bleomycin-induced lung injury in SPARC knock out (KO) mice.
This model demonstrated that in SPARC KO animals, there was
increased neutrophil recruitment to the sites of acute inflammation
with enhanced levels of inflammation, but not necessarily with the
development of fibrosis [10].
The pro-inflammatory cytokines such as interleukin (IL)-1b, IL-
6 and tumour necrosis factor (TNF)-a promote inflammation,
which is central to leucocyte recruitment and activation with the
secretion of various growth factors including platelet derived
growth factor and transforming growth factor (TGF)-b. SPARC
has been suggested to modulate inflammation through the
regulation of cytokine and chemokine bioavailability through its
effects on the production and activity of metalloproteinases
(MMPs) such as MMP-2 and MMP-3 [11,12]. The increase in
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these MMPs enhances the cleavage of pro-IL1b to active IL-1b
[13] and thus the development of inflammation [14,15].
Through endoscopic, clinical and histological evaluation,
together with the determination of pro-inflammatory cytokines
levels within the colonic tissue, this study aimed to investigate the
contribution that SPARC may have on the development of
intestinal inflammation. SPARC KO and wild type (WT) mice
received DSS to induce an acute colitis and were assessed over
time for tissue reconstitution. The findings demonstrated that
SPARC KO mice had significantly less inflammation, including
lower endoscopic and histology scores with more regulatory T
(Treg) cells, and less inflammatory cells in combination with lower
pro-inflammatory cytokine levels and a possible faster healing rate.
These findings suggest that SPARC is able to enhance inflamma-
tion in the DSS induced murine model of colitis.
Materials and Methods
Ethics Statement
The care and use of the animals and experimental protocol
were approved by the Animal Ethics Committee (AEC) of the
University of Western Australia (Animal ethics number: RA/3/
100/606).
129/SvJ6C57/BL6 WT and SPARC KO mice were obtained
as a gift from Dr E. Helene. Sage, Hope Heart Institute,
Washington State, USA on a mixed background [16]. Animals
were maintained under specific pathogen free conditions. Unless
specifically stated, female mice aged 10–12 weeks were used in all
experiments. Only female mice were used in order to reduce
potential variability between the findings, ease of use and the lack
of aggressive behavior that necessitates the male mice being caged
separately. Mice were allowed food and water al libitum.
Confirmation of complete ablation of SPARC gene was demon-
strated in all SPARC null mice by genotyping using PCR.
DSS induction of colitis
Colitis was induced by the addition of DSS [3% (wt/vol) (MP
Biomedicals LLC, Aus)] to the drinking tap water for 7 days.
Control mice received plain tap water without DSS. As the
efficacy of DSS varies between batches, the majority of the
experiments were undertaken using the same batch number. Each
new DSS batch was tested for efficacy. Following induction there
was a recovery period of 1–7 weeks without DSS (Figure 1). The
mean daily DSS-water consumption was recorded for each group.
Mice were assessed daily during the treatment period with body
weights and stool samples examined, and weekly during the
recovery period.
Endoscopic monitoring of colitis
A high resolution mouse video endoscopic system was used to
assess the level of colitis and the mice were routinely scoped 1 day
prior to sacrifice. Mice were anaesthetised using an intraperitoneal
ketamine/xylazil injection of a 0.01 ml/g body weight. The
experimental endoscopy setup, denoted "Coloview system", consisted
of a miniature endoscope (scope 1.9 mm outer diameter), a xenon
light source, a triple chip camera, and an air pump (Karl Storz,
Germany) to achieve regulated inflation of the mouse colon. The
endoscopic procedure was viewed on a colour monitor and
digitally recorded. All endoscopic procedures were blindly
assessed.
The level of colitis was determined using the modified murine
endoscopic score of colitis severity (MEICS) [17]. The MEICS
system consists of 5 parameters: Thickening of the colon wall,
changes of the normal vascular pattern, presence of fibrin, mucosal
granularity and stool consistency. Endoscopic grading was
performed for each parameter (scored between 0 and 3) leading
to a cumulative score of between 0 (no signs of inflammation) and
15 (endoscopic signs of very severe inflammation). Healthy mice
usually have a score of 0–3.
Tissue dissection
The colon was removed and the length measured from the anus
to caecum. Approximately 1 mm from the anus was discarded to
remove the rectum as it has a different tissue fibro-structure to the
colon. The spleen and mesenteric lymph nodes were removed
stored in supplemented DMEM (GibcoH Invitrogen Co., Aus) and
kept on ice until use. Colonic tissue for cytokine detection was
washed in RPMI-1640 (GibcoH Invitrogen Co., Aus) supplement-
ed with antibiotics. The tissues were placed in 96 well trays
containing serum free RPMI-1640 supplemented with antibiotics
for 24 hours. The culture supernatants were collected, spun at
12000 g at 4uC, snap frozen and stored at –80uC until use.
Preparation of paraffin sections
Colonic tissue was cleaned, formalin-fixed and embedded in
paraffin wax. Sections, 4.5mm thick were dried at 55uC overnight
and stored at room temperature (RT) until stained with
haemotocylin and eosin (H&E) using the Shandon LinistainTM
GLX Linear Stainer (Thermo Scientific, AUS).
All H&E stained paraffin sections were assessed blindly by
specialist gastroenterological histopathologist according to the
scoring system by Dieleman et al [18]. In this scoring system, 4
features are graded: The severity and depth of inflammation are
each scored from 0–3, while the level of crypt damage and
regeneration are each scored between 0 and 4. These changes were
also quantified as to the percentage of the total colonic circumference
that was involvement by the disease process: i) 1–25%; ii) 26–50%;
Figure 1. Overview of the experimental design to investigate acute and recovery phase. Mice receiving DSS for 7 days were used to
examine the acute inflammatory response. Mice that received 3% DSS for 7 days followed by plain tap water for 1, 2 and 4 weeks (D14, D21 and D35
respectively) were used to investigate the recovery. Age matched control groups (non DSS treated) were present for each time point. (q represents
points of analysis).
doi:10.1371/journal.pone.0077575.g001
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iii) 51–75%; iv) 76–100%. A histological score (between 0–56) was
calculated for each sample based on multiplying the score of each
feature by the percentage of the tissue involved and adding the totals
together. At the day 35 time-point, the inflammation severity and
regeneration scores were added and compared using chi square by
SPSS (Version 19, IBM, USA).
Immunofluorescent staining of cryosections
Colons were embedded in Tissue-TekH O.C.T freezing medium
(ProSciTech, Aus), snap frozen in liquid nitrogen and stored at –
80uC. The tissues were cut into 7mm thick sections on a freezing
microtome cryostat chamber and sections mounted onto Super-
frostTM slides, dried at RT and stored at –80uC. Prior to use, slides
were fixed in ice cold acetone for 2 minutes, rehydrated in PBS
and blocked with 5% goat serum. The sections were incubated in
the optimal concentration of rat monoclonal primary antibody
(CD68, Kp1, 1:400, abcam, USA; Ly6G 1A8, 1:400, Biolegend,
USA; F4/80 CI:A3-1, 1:200, AbD serotec, USA; CD 11b, M1/
70, 1:400, BD Pharmingen, USA) prepared in commercial
antibody diluent (DAKO, Denmark) overnight at 4uC and then
washed 3 times for 10 minutes in PBS. The sections were then
incubated in goat anti-rat IgG secondary antibody conjugated to
Alexa FluorH 594 (Invitrogen Co., USA) for 1 hour at RT in a
dark, humidified chamber. After washing a further 3 times in PBS,
slides were mounted with Prolong Gold Antifade reagent with
DAPI (Invitrogen Co., Aus). Slides were viewed and photographed
with Olympus IX-81 inverted fluorescence microscope. The DAPI
stained nuclei blue when viewed under the ultra violet (UV) filter
while the proteins of interest stained red when view with green
filter. Each section was viewed at x200 magnification and
photographed. The numbers of positive cells were counted in 5–
15 fields.
Detection of cytokines
A customized 15plex BDTM Cytometric bead array (CBA) Flex
set was used to detect the following cytokines and chemokines
simultaneously in the tissue explants and serum samples from
individual mice: IL-1b, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-
12/IL23p40, TNF-a, IFN-c; RANTES, MCP-1, MIP-1a, MIP-
1b, MIG. Supernatants from tissue explants were used undiluted
(except 1:60 for IL-6 analysis). The assay was set up in multiscreen
HTS filter plates (Milipore, USA) and performed according to the
manufacturer’s instructions. A typical standard was obtained by
serial dilution of recombinant protein. Samples were analysed on a
BD FACSCantoTM instrument using BD FACSDIVATM software
and BD FCAP ArrayTM software. All cytokines were measured at
the protein level without ex vivo stimulation of the cells/tissues
(serum free) as this may reflect the in vivo conditions better [5].
To measure TGF-b protein levels the QuantikineH mouse/rat/
porcine/canine immunoassy for mouse TGF-b (R&D Systems,
Aus) was used according to the manufacturer’s instructions
modified to include neutralisation of the sample with 2.4 N
NaOH instead of 1.2N NaOH following activation with acid. The
explant culture supernatants were diluted 1.3 fold following
sample activation. Recombinant protein from 31.2 to 2000 pg/ml
served as a standard curve.
Flow cytometry analysis
Single cell suspensions from the spleen and mesenteric lymph
nodes (MLN) were filtered through a 40mm wire mesh and the red
blood cells were lysed with red cell lysis buffer. The single cells
were suspended in supplemented DMEM at 4uC till staining. All
staining for Treg cells was performed using the mouse regulatory
T cell staining kit (eBioscience, USA) according to the manufac-
turer’s instructions.
All data were collected with BD FACSCantoTM instrument
using BD FACSDIVATM software with analysis by FlowJo
software (version 7.6, Tree Star Inc, USA). The lymphocyte
population was identified on the basis of size and granularity. The
lymphocytes were further characterized by their cell surface
markers. All gating was set based on the appropriate isotype
control. In order to quantify the regulatory T cells, the CD4+
Figure 2. Micro-endoscopic images of WT and SPARC KO mice
after DSS treatment. Representative endoscopic images at day 6
showing the colon of healthy control (A, B, C, D), DSS-treated WT (E, F,
G, H) and DSS-treated SPARC KO (I, J, K, L) mice. When treated with DSS
for 7 days, both WT and SPARC KO mice showed signs of inflammation:
loose and bloody stool (solid triangle in E, I), thickening of colonic wall
with reduction in translucency (F, J), altered vascular pattern (open
triangle in F, J) and present of fibrin (arrow in G, K). The lowest panel (D,
H, L) showed the colon closest to rectum, which has a different
fibrosturcture to the distal and proximal colon.
doi:10.1371/journal.pone.0077575.g002
Figure 3. MEICS of WT and SPARC KO mice. Line graph comparing
SPARC KO-DSS to WT-DSS mice at difference time points. Values are
mean 6 SEM based on records of 8–15 mice per time point from 3
different experiments (*p,0.05, ***p,0.001).
doi:10.1371/journal.pone.0077575.g003
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CD25+ population within the lymphocyte population was selected
and further gating with FoxP3 was used to analyse Treg cells. For
each sample 100 000 gated lymphocyte events were recorded. The
results represent the pooled data of mean percentage of cells of
interest out of the total gated cells from 1–3 independent
experiments.
Statistical Analysis
Statistical significance was calculated using GraphPad Prism
(Version 5.0) (GraphPad software, Inc, USA). All graphs and
comparison of differences between groups were assessed using
Student’s unpaired t-test unless otherwise mentioned. The data
from the cell counting of the immunofluorescence sections were
sampled from a Poisson distribution, the analysis applied was
loglinear regression, and the differences between WT and SPARC
KO mice were compared using a logliner regression analysis by
SPSS (Version 19, IBM, USA).
Results
Clinical symptoms, endoscopic and histopathalogical
inflammation
All DSS-treated mice demonstrated body weight loss and
bloody liquid stools 2–7 days after commencing DSS. The WT
mice had a greater percentage of weight loss than SPARC KO
mice although this was not statistically significant (WT: 28.09% vs
SPARC KO: 12.36%, p = 0.08). Both groups, however, regained
the lost weight once DSS treatment was ceased.
Endoscopically, untreated control mice had solid stool, clearly
visible vascularity with translucency of the intestinal wall (Figure 2
A, B, C). By contrast, there was endoscopic inflammation that was
maximal in the distal 2–3 cms of the colon, in all the DSS-treated
animals. On day 6, using the MEICS, both the WT and SPARC
KO mice demonstrated marked endoscopic signs of mucosal
inflammation with soft, poorly formed and bloody stools (solid
triangle in Figure 2 E, I), mucosa thickening (Figure 2 F, J),
spontaneous bleeding, loss of visible blood vessel structures (open
triangle in Figure 2 F, J), and the presence of fibrin (arrow in
Figure 2 G, K). All these features were noted to be worse in the
WT DSS-treated mice indicating a greater level of inflammation.
Of note was the greater level of bleeding, mucosal thickening and
changes in the vascular pattern in the DSS-treated WT animals
(Figure 2 E, F, G) compared to the SPARC KO mice (Figure 2
I, J, K).
While the untreated controls all had a score MEICS of 0, the
WT animals had higher MEICS scores than SPARC KO mice at
days 6 (p = 0.039), 14 (p = 0.067), 20 (p = 0.019) and 34
(p,0.0001) (Figure 3). After DSS removal, the stool reverted to
normal and the colonic wall translucency and vascular pattern
gradually returned to normal by day 13 and remained endoscop-
ically normal at days 20 and 34. Granularity of the mucosa surface
consistent with ongoing inflammation, however, was observed in
the distal colon at day 34 in the WT animals (Image not shown).
The untreated WT and SPARC KO controls all had a
histological score of 0, while the DSS-treated SPARC KO animals
had a lower histological inflammatory score (Figure 4B) than the
WT mice but this did not reach statistical significance. At day 7,
moderate to severe inflammation was seen in both WT and
SPARC KO mice, with transmural inflammation particularly seen
in the WT animals. There was colonic crypt lost with a reduction
in the goblet cell numbers, focal ulceration inflammatory cell
infiltration (slim arrow in Figure 4A) and oedema of the
submucosa (# in Figure 4A). Between days 14 to 35, regeneration
was identified by re-epithelisation and proliferation of new crypts.
Figure 4. Histological assessment of SPARC KO and WT colons. A) Representative photographs of H&E-stained sections of the distal colon at
day 7 demonstrating ulceration, mononuclear cell infiltrate involving part to all of the colonic wall with disruption of the normal crypt architecture
and loss of goblet cells (slim arrow) and submucoa oedema (#). Bar: 100 mm. B) Extent of inflammation quantified and expressed as an inflammation
score. Each time point consisted of 10–15 mice from 3 different experiments. Value is mean 6 SEM. (*p,0.05)
doi:10.1371/journal.pone.0077575.g004
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DSS-treated WT mice, however, still demonstrated mucosal crypt
damage and ulceration at day 21 in contrast to the mucosal
reconstitution observed in the SPARC KO mice (Image not
shown). By day 35, based on the inflammation severity and
regeneration subscores as described by Dieleman et al [18], all the
SPARC KO DSS-treated mice (n = 13) had completely resolved
the colonic mucosal inflammation, while 50% (7/14) of WT DSS-
treated animals still demonstrated mucosal inflammation (x2
(1) = 8.78, p,0.01).
Colonic cytokine production
No differences were observed between the untreated WT and
SPARC KO control mice for the pro-inflammatory cytokines IL-
1b, IL-6 or TNF-a at any time point and had less cytokine
secretion than all the DSS-treated animals at all time points
(p,0.05). The DSS-treated animals demonstrated significantly
elevated levels of IL-1b (p,0.01; Figure 5A), IL6 (p = 0.03, Data
not shown) and TNF-a (p = 0.029; Data not shown) at day 7
compared to untreated controls. The levels fell rapidly following
DSS withdrawal. WT DSS-treated animals demonstrated higher
levels of IL-1b, IL6 and TNF-a compared to the SPARC KO
mice at all time points and these correlated with the MEICS and
histological scores. Only IL-1b secretion (Figure 5A) at day 7,
however, was significantly higher in WT DSS-treated animals
compared to the DSS-treated SPARC KO mice (p = 0.025).
As chemokines are critical elements in regulating cell trafficking
to inflammatory sites [19] these were also measured. MIG
(monokines induced by IFN-c) was detected in the untreated
animals and was significantly induced following DSS treatment at
7 days in WT animals (p = 0.011, Figure 5B) and also in SPARC
KO animals but to a lesser extent. MIG protein levels were
significantly higher in DSS-treated WT mice (Figure 5B)
compared to DSS-treated SPARC KO mice at day 7 (p = 0.031)
and 14 (p = 0.014).
TGF-b1 proteins levels were also significantly higher in DSS-
treated SPARC KO compared to WT animals at day 7 (p = 0.017;
Figure 5C). There were no significant differences in the secretion
patterns observed between the WT and SPARC KO animals after
DSS treatment for the Th-1 (IFN- c), Th-2 (IL-4, IL-5, IL-13), and
Th-17 (IL-17A, IL-12/IL23p40) related cytokine levels. No
significant trend was observed for the anti-inflammatory IL-10
cytokine and other chemokines (RANTES, MCP-1, MIP-1a,
MIP-1b) measured in this study as well.
Figure 5. IL-1b, MIG and TGF-b1 production in the colon of WT
and SPARC KO mice measured with CBA and ELISA. Mean 6
SEM, *p = 0.05 when comparing WT-DSS mice to SPARC KO-DSS mice;
# p = 0.05, ##p,0.01 when comparing untreated WT mice to WT-DSS
mice (n = 10–20 mice per group from 3 different experiments per time
point).
doi:10.1371/journal.pone.0077575.g005
Figure 6. Percentage of Treg cells (CD4+CD25+FoxP3+) in the
spleen (A) and MLN (B) from SPARC KO and WT mice. Cells were
isolated from spleen and MLN on day 7, 14, 21, and 35 following DSS
treatment and determined by flow cytometry. Data represent the mean
percentage of Treg cells 6 SEM from 3 independent experiments each
consisting of 4-5 animals; *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0077575.g006
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Treg cells levels
The percentage of Treg cells (CD4+CD25+FoxP3) was higher
in the spleen (13.2% vs 15.8%; p,0.01) and MLNs (8.55% vs
11.14%; p = 0.013) of untreated SPARC KO compared to WT
mice (Data not shown). Following DSS-treatment Treg cell
percentages were also increased in the SPARC KO mice above
that of the WT animals at day 14 in both the spleen (p,0.01) and
MLN (p,0.01); percentages were also increase at day 21 in the
spleen (p,0.01) (Figure 6).
Innate cell pattern in WT and SPARC KO Mice. In
control animals, consistent with the absence of inflammation, there
were almost no neutrophils present and those that were present
were located within the lamina propria (LP). Following DSS
treatment in both groups, greater numbers of neutrophils were
observed in the LP and submucosa, particularly at sites of
ulceration (Figure 7). Ly6G+ cells (a neutrophil marker) were
significantly more abundant in DSS-treated WT animals than in
SPARC KO mice at day 21 (1.69 fold, p,0.001) and 35 (9.93 fold,
p,0.001) consistent with more inflammation.
In control mice, CD68+ cells (a macrophage marker) were
located primarily in the LP, with low numbers also detected in the
submucosa. Following DSS treatment, CD68+ cells increased with
greater cell numbers located within the submucosa (Figure 7). WT
animals had statistically greater numbers of CD68+ cells than
SPARC KO mice following DSS treatment at day 14, (1.36 fold,
p,0.001), 21 (1.45 fold, p,0.001) and 35 (1.50 fold, p,0.001)
again consistent with a greater level of inflammation. When stained
with another macrophage marker, F4/80, a similar trend was
observed. At day 14 (1.07 fold, p,0.001) and 21 (1.69 fold,
p,0.001), F4/80+ cells were observed to be greater in the WT-DSS
mice in both LP and submucosa when compared to the DSS-treated
SPARC KO mice (Figure 7; Day 7 and 35 time points were not
investigated). CD11b was also assessed and this stains for
macrophages, monocytes and neutrophils (Figure 7). More
CD11b+ cells were observed in the DSS-treated WT compared to
the DSS-treated KO mice at day 21 (1.09 fold, p = 0.02) and 35
(1.18 fold, p,0.001) in line with greater levels of inflammation in
the WT animals.
Discussion
SPARC can play an active role in cell migration, tissue
regulation and wound healing [6,20-22]. A role for SPARC in the
colon, however, has not been studied and the literature suggests
that the role of SPARC in inflammation could be both organ and
model specific [9,10,23]. As the DSS-induced colitis model
exhibits inflammatory and histopathological features that are
similar to human colitis, it can be used as a model to assess the
effect of the presence of SPARC and its role in the colonic
inflammation of IBD [2,18,24,25].
Ingestion of DSS for 7–10 days induces acute inflammation
[1,4,5,26]. Chronic inflammation can also be achieved by the
administration of 3–5 cycles of DSS with a DSS-free period
between each cycle [1]. A single DSS cycle, however, is sufficient
to induce chronicity in the C57BL/6 mice and was used in this
study [5]. The data presented, however, demonstrated a potential
pro-inflammatory role for SPARC in the DSS-induced model of
murine colitis. The clinical parameters of colitis were all noticeably
less in the SPARC KO mice and these were accompanied by
significantly lower micro-endoscopic inflammatory scores. Of
note, WT mice had a tendency to develop a chronic, slow healing
inflammation when all of the SPARC KO mice had fully resolved
the intestinal inflammation by the end of the study.
Endoscopic examination of the colon is important for the
diagnosis and assessment of colonic diseases. The use of the mouse
micro-endoscopic system provided valuable and accurate infor-
mation in the assessment and monitoring of the intestinal
inflammation and its resolution [17] and it clearly demonstrated
less inflammation in the KO animals. The endoscopic scoring also
appears to be a more sensitive method of evaluating inflammation
levels than either histology, or the use of surrogate markers used to
evaluation disease activity such as weight loss and stool consisten-
cy.
At day 7, both, WT and SPARC KO DSS-treated animals,
showed similar levels of histological inflammation, but the SPARC
KO mice had less severe inflammation at each subsequent time
point. This suggests that the SPARC KO animals may be able to
heal more rapidly. The regeneration sub-score alone, however, did
not detect any difference suggesting that the histology scoring of
colonic regeneration is difficult and not particularly sensitive.
Regeneration, however, can only be assessed following the peak of
inflammation (day 7) but histological assessment was only possible
at weekly intervals. This raises the possibility that the point of peak
regeneration may have been missed in the SPARC KO animals.
One solution to this limitation may be the inclusion of more time
points over a shorter time interval, this, however, was not feasible
in this study.
SPARC effects on wound healing appear to vary depending on
the tissue type, but the findings in this study are similar to those of
Bradshaw and colleagues where accelerated cutaneous wound
healing was observed in SPARC-null mice [27]. The anti-
proliferative properties of SPARC [6] may also be a potential
cause of a slower healing in the WT animals as re-epithelialisation
principally begins with proliferation of the neighbouring epithelium
Figure 7. Ly6G+, CD68+ F4/80+ and CD 11b+ cellular levels in
WT and SPARC KO colons after DSS treatment. Representative
images of in situ visualisation of colonic neutrophils and macrophages.
Positive staining (red) and co-stained nuclei (blue). Bar: 100 mm
doi:10.1371/journal.pone.0077575.g007
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[18]. If indeed SPARC KO animals heal faster than their WT
littermates then this could also be related to the inhibition by
SPARC of other important mediators in healing like platelet derived
growth factor, vascular endothelial growth factor and basic
fibroblast growth factor. In addition, the dermal structure of
SPARC KO mice has been shown to be different to WT animals
with smaller collagen fibrils suggesting an alteration in collagen
bundling in the absence of SPARC. These findings were support the
concept that a less structured ECM would allow for a faster cellular
migration resulting in faster healing [20,28].
Cytokines and chemokines interact in a complex and integrated
way and are central to the pathogenesis of IBD and this study
evaluated a wide range of cytokines and chemokines [29,30]. It is
known that SPARC can enhance macrophage, neutrophil and
epithelial cell migration [31,32] and it is primarily these cells that
secrete the pro-inflammatory cytokines IL-6, IL-1b and TNF-a
[5]. IL-1b is secreted by macrophages and its activation within the
mucosa and sub-mucosa [33,34] induces and perpetuates human
colitis [35]. The tissue damage observed in WT animals would
thus be enhanced by the greater levels of the pro-inflammatory
cytokines observed in this study. Macrophages are also thought to
be the major source of MIG and their presence within the
intestinal mucosa may be able to shift the cytokine profile from a
predominance of TNF-a/IL-1 to IFN-c and subsequently to MIG
[36]. MIG has recently been shown to play a role in mediating T
cell recruitment to site of inflammation in the heart tissue [37] and
its expression is elevated in mixed cellularity subtype of Hodgkin’s
lymphoma patients where this disease is thought to be similar to
the inflammatory phase observed in wound healing process [38].
With lower chemokine levels, migration of leucocytes, especially
neutrophils, into the colon of the SPARC KO animals would be
reduced. A similar effect can also be observed in chemokine
receptor-deficient mice, which are protected from the DSS-
induced inflammation due to less infiltration by immune cells
[29,39].
The SPARC KO animals were observed to have higher colonic
TGF-b1 levels, which contrasted with the report by Socha and
colleagues that found lower TGF-b expression in the kidney in the
absence of SPARC [9]. It is unclear why more TGF-b was
observed in SPARC KO colons, but it may be secondary to the
unique immune adaptations of the colon which is colonised with
great numbers of Treg cells that are able to modulate the
immunosuppressive activity of TGF-b. In addition, the intestinal
mucosa promotes epithelial restitution after injury through the
increased production of bioactive TGF-b1 by the epithelial cells
[40] and subepithelial myofibroblasts [41] and thus the increase in
TGF-b1 may contribute to the maintenance of intestinal barrier
integrity and intestinal healing in SPARC KO mice resulting in
less inflammation.
In summary, this study demonstrates that SPARC is associated
with increased inflammation in the DSS-induced model of colonic
inflammation, which seems to be associated with a longer time to
tissue healing. This is most likely secondary to SPARC’s effect on
cell migration and ECM regulation, which subsequently modulate
the inflammatory cell infiltration and the secretion of pro-
inflammatory cytokines.
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